John Cox, MBA Chief Executive Officer
John became the first CEO of Repertoire Immune Medicines when, as Chairman of Torque Therapeutics, he led its merger with Cogen Immune Medicine to form Repertoire. Prior to joining Repertoire, he led the spin-out of Bioverativ from Biogen in 2016, building the company from a new venture with two drugs for the treatment of hemophilia A and B to a global organization with revenue of more than $1 billion before its acquisition by Sanofi in 2018 for $11.6 billion. In 13 years with Biogen, John built and operated a global supply chain, and created and ran Biogen’s biosimilars business. From October 2015 to May 2016, John also served as interim Executive Vice President, Global Therapeutic Operations, responsible for Biogen’s therapeutic groups of Specialty Medicines and Rare Diseases, which included responsibility for the global commercial performance of Biogen’s marketed products. John earned a BS degree from Arizona State University and MS in cell biology from California State University, Hayward. He also holds an MBA from the University of Michigan Stephen M. Ross School of Business.